Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01168921 · ClinicalTrials.gov registry record · Phase 2
Phase II Eltrombopag in Chronic Lymphocytic Leukemia (CLL)
A Phase 2 study of Leukemia and CLL, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
- 1
- Study location
NCT01168921 is a Phase 2 study of Leukemia and CLL that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 23 participants, below the 487-participant average among 233 other Leukemia trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01168921, a Phase 2 study of Leukemia and CLL, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical research study is to learn if eltrombopag can help to increase the number of platelets in patients with CLL. The safety of this drug will also be studied.
Interventions
- DRUG Eltrombopag
Study Locations (1)
Texas
- University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2010-11-03 |
| Est. Completion | 2022-03-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01168921
The ClinicalTrials.gov registry entry for NCT01168921 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 487-participant average among 233 other Leukemia trials with a reported enrollment target (95% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Leukemia appearing as the primary indexed condition, and to 1 intervention - of which Eltrombopag is the first listed.
NCT01168921 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT01168921 about?
NCT01168921 is a clinical study titled "Phase II Eltrombopag in Chronic Lymphocytic Leukemia (CLL)". The goal of this clinical research study is to learn if eltrombopag can help to increase the number of platelets in patients with CLL. The safety of this drug will also be studied.
What is the current status of trial NCT01168921?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2010-11-03. Estimated completion is 2022-03-07.
What conditions does trial NCT01168921 study?
This clinical trial studies the following conditions: Leukemia, CLL.
What interventions are being tested in trial NCT01168921?
The interventions under investigation include: Eltrombopag (DRUG).
Who is sponsoring clinical trial NCT01168921?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01168921 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
RECRUITING · Phase 2
-
Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)
RECRUITING · Phase 2
-
Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia
RECRUITING · Phase 2
-
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
RECRUITING · Phase 2
-
Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation
RECRUITING · Phase 2
-
A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.